Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New guidance on stem cell therapies
Stem cell medicines are produced in large batches which need to be sterile.
Document addresses concerns raised on sterility 

The first ever guidance for stem cell-based therapies in animals has been-been published by the European Medicines Agency (EMA).

The guidance follows a review of scientific evidence by the Committee for Medicinal Products for Veterinary Use (CVMP), which identified the sterility of stem-cell therapies as a ‘priority area’.

Taking the form of a question and answer document, the guidance addresses eight main concerns raised by manufacturers and authorities with regards to ensuring sterile and safe stem cell-based therapies.

Veterinary stem cell medicines originate from tissues from a donor from the same species of animal. They are produced in large batches which need to be sterile as they are administered by injection into the body.

Contamination can occur at various stages - from the initial sampling of cells and tissues, up to the final packaging into vials, syringes or bottles. The EMA states that the most critical step is the sourcing and collection of the stem cells as it is not always possible to put in place aseptic techniques at this stage.

Up to now, there has been no specific guidance from the EMA on how stem cell-based veterinary medicine should be used. Guidance documents have been produced for human cell-based products or for general requirements on animal cell-based products in the USA.

In recent years, interest and research into new therapies such as stem cell or gene therapy has gathered speed. In 2014, the EMA established an Ad Hoc expert group of veterinary novel therapies to provide general guidance on the requirements of novel veterinary medicines.

The EMA defines novel therapies as therapies that are entirely new to the veterinary sector. This is because they are genuinely new and have not been used in animals before, or new only to the veterinary sphere, but well known in human medicine.

 

 

 

Become a member or log in to add this story to your CPD history

Birmingham Dogs Home makes urgent appeal

News Story 1
 Birmingham Dogs Home has issued an urgent winter appeal as it faces more challenges over the Christmas period.

The rescue centre has seen a dramatic increase in dogs coming into its care, and is currently caring for over 200 dogs. With rising costs and dropping temperatures, the charity is calling for urgent support.

It costs the charity £6,000 per day to continue its work.

Fi Harrison, head of fundraising and communications, said: "It's heart-breaking for our team to see the conditions some dogs arrive in. We really are their last chance and hope of survival."

More information about the appeal can be found here

Click here for more...
News Shorts
Avian flu confirmed at premises in Cornwall

A case of highly pathogenic avian influenza H5N1 has been detected in commercial poultry at a premises near Rosudgeon, Cornwall.

All poultry on the infected site will be humanely culled, and a 3km protection zone and 10km surveillance zone have been put in place. Poultry and other captive birds in the 3km protection zone must be housed.

The case is the second avian flu case confirmed in commercial poultry this month. The H5N5 strain was detected in a premises near Hornsea, East Riding of Yorkshire, in early November. Before then, the disease had not been confirmed in captive birds in England since February.

The UK chief veterinary officer has urged bird keepers to remain alert and practise robust biosecurity.

A map of the disease control zones can be found here.